The statins: multifunctional antithrombotic and antineoplastic drugs.

Abstract:

:Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among many shared by this class of drugs. Most statins appear to have antithrombotic activity that is unrelated to the ability to reduce cholesterol levels, and several have significant antitumor effects. This article reviews the laboratory and clinical evidence that statins have antithrombotic and anticancer activity, discusses the ways in which these two activities intersect, and proposes novel uses for statins for the treatment of conditions other than hypercholesterolemia.

journal_name

Semin Thromb Hemost

authors

Splichal JE,Stamm JA,Ornstein DL

doi

10.1055/s-2003-40964

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

259-74

issue

3

eissn

0094-6176

issn

1098-9064

journal_volume

29

pub_type

杂志文章,评审
  • Relationship between ABO blood group and hemorrhage: a systematic literature review and meta-analysis.

    abstract::Several studies have suggested that patients with non-O blood group have an increased risk of both venous and arterial thromboembolic events. On the contrary, the role of ABO blood group on the risk of bleeding complications remains unclear. Thus, we performed a meta-analysis of the literature with the aim of assessin...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,meta分析,评审

    doi:10.1055/s-0032-1329550

    authors: Dentali F,Sironi AP,Ageno W,Bonfanti C,Crestani S,Frattini F,Steidl L,Franchini M

    更新日期:2013-02-01 00:00:00

  • The Complications of Vascular Access in Hemodialysis.

    abstract::Complications related to hemodialysis vascular access continue to have a major impact on morbidity and mortality. Vascular access dysfunction is the single most important factor that determines the quality of dialysis treatment. Vascular access stenosis is a common complication that develops in a great majority of pat...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0037-1606180

    authors: Masud A,Costanzo EJ,Zuckerman R,Asif A

    更新日期:2018-02-01 00:00:00

  • Prothrombin-related antigens in human aortic intima.

    abstract::Most plasma proteins are present in both normal and atherosclerotic intima, and their concentrations in intimal interstitial fluid are directly related to plasma concentration and molecular size. All intimal samples also contain soluble fibrin-fibrinogen-related antigens, consisting of variable mixtures of fibrinogen ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-999030

    authors: Smith EB,Crosbie L,Carey S

    更新日期:1996-01-01 00:00:00

  • Management of musculoskeletal complications of hemophilia.

    abstract::Prophylactic treatment from ages 2 to 18 years could prevent the development of hemophilic arthropathy if the concentration of the patient's deficient factor is kept from falling below 1% of normal. Early treatment is of paramount importance because the immature skeleton is very sensitive to the complications of hemop...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2003-37942

    authors: Rodriguez-Merchan EC

    更新日期:2003-02-01 00:00:00

  • Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience.

    abstract::Natural inhibitors of coagulation, in other words, antithrombin (AT), the protein C system, and tissue factor pathway inhibitor (TFPI), play an important role in controlling the activation of coagulation during disseminated intravascular coagulation (DIC). Furthermore, they may not only influence coagulation but also ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2001-18871

    authors: de Jonge E,van der Poll T,Kesecioglu J,Levi M

    更新日期:2001-12-01 00:00:00

  • The UK National External Quality Assessment Scheme for heritable bleeding disorders.

    abstract::Molecular genetic analysis of families with hemophilia and other heritable bleeding disorders is a frequently requested laboratory investigation. In the United Kingdom, laboratories undertaking genetic testing must participate in a recognized external quality assessment scheme for formal accreditation. The UK National...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0034-1365843

    authors: Perry DJ,Cumming T,Goodeve A,Hill M,Jennings I,Kitchen S,Walker I

    更新日期:2014-03-01 00:00:00

  • Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.

    abstract::Endothelial cells secrete von Willebrand factor (vWF) multimers that are larger than those found in the circulating plasma. These very large multimeric forms of vWF, capable of spontaneously binding to and agglutinating the blood platelets under conditions of high fluid shear rate, are degraded by a specific metallopr...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2002-27819

    authors: Furlan M,Lämmle B

    更新日期:2002-04-01 00:00:00

  • Metabolic modulation of inflammation-induced activation of coagulation.

    abstract::The bidirectional interaction between coagulation and inflammation, which is relevant in various disease states that are dominated by systemic inflammatory responses, such as severe infection or chronic vascular disease, is modulated by metabolic factors. Changes in lipoprotein metabolism affect the inflammation-induc...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2008-1066020

    authors: Levi M,Nieuwdorp M,van der Poll T,Stroes E

    更新日期:2008-02-01 00:00:00

  • Clinical syndromes associated with lupus anticoagulants.

    abstract::Recent evidence suggests that lupus anticoagulants are immunologically distinct from the anticardiolipin antibodies. Nevertheless, the associated clinical complications exhibited by the two groups of antibodies are similar. They have been shown to have a strong association with a history of arterial and venous thrombo...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-1001886

    authors: Kampe CE

    更新日期:1994-01-01 00:00:00

  • Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies.

    abstract::Disseminated intravascular coagulation (DIC) is a syndrome characterized by systemic intravascular activation of coagulation leading to widespread deposition of fibrin in the circulation. There is ample experimental and pathological evidence that the fibrin deposition contributes to multiple organ failure. The massive...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2001-18862

    authors: Levi M,de Jonge E,van der Poll T,ten Cate H

    更新日期:2001-12-01 00:00:00

  • Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency.

    abstract::Protein C replacement therapy with a monoclonal antibody purified, virus inactivated protein C concentrate was carried out in nine infants (three male, six female) with severe congenital protein C deficiency and life-threatening purpura fulminans and/or thrombosis associated with disseminated intravascular coagulation...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-1000658

    authors: Dreyfus M,Masterson M,David M,Rivard GE,Müller FM,Kreuz W,Beeg T,Minford A,Allgrove J,Cohen JD

    更新日期:1995-01-01 00:00:00

  • Targeting Nanotechnologies for the Treatment of Thrombosis and Cardiovascular Disease.

    abstract::Thrombosis is characterized by the formation of in vivo blood clots that are localized within arterial or venous blood vessels. These thrombi form beyond the need for physiologically healthy hemostatic responses and can lead to significant medical issues for affected individuals. Unfortunately, the existing standard-o...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0039-1697946

    authors: Palazzolo JS,Westein E,Hagemeyer CE,Wang TY

    更新日期:2020-07-01 00:00:00

  • Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

    abstract::In order to assess inhibitor development in previously untreated patients (PUPs) with severe (factor VIII [FVIII]<1%) and moderate (FVIII 1 to 5%) hemophilia A, a prospective study was initiated in 1976. During the 23-year study period, 72 hemophiliacs were frequently exposed prophylactically or on demand to plasma-de...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2002-32664

    authors: Kreuz W,Ettingshausen CE,Zyschka A,Oldenburg J,Saguer IM,Ehrenforth S,Klingebiel T

    更新日期:2002-06-01 00:00:00

  • Shear-induced pathway of platelet function in cardiac surgery.

    abstract::The contribution of platelet dysfunction to the impaired hemostasis after cardiac surgery remains to be established, because there is no sensitive method to assess platelet function. Measurement of the shear-induced pathway of platelet function, an important mechanism in inducing hemostasis, became possible by a novel...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0032-1313605

    authors: Tabuchi N,Tigchelaar I,van Oeveren W

    更新日期:1995-01-01 00:00:00

  • Monitoring Antiplatelet Therapy.

    abstract::The increasing use of antiplatelet therapy, particularly aspirin and oral P2Y12 inhibitors, in the prevention and management of arterial thrombosis, has stimulated extensive pharmacodynamic studies and research into tailored antiplatelet regimens. Many different methodologies have been studied for monitoring antiplate...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0036-1597298

    authors: Orme R,Judge HM,Storey RF

    更新日期:2017-04-01 00:00:00

  • Management of bleeding complications of hematologic malignancies.

    abstract::Persons with hematologic malignancies bleed for a variety of reasons, including alterations in platelet function and numbers, clotting factor deficiencies, circulating anticoagulants, and defects in vascular integrity. The management of bleeding begins with a full characterization of the hemostatic defect. Vitamin K d...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-976178

    authors: Green D

    更新日期:2007-06-01 00:00:00

  • Factor v Leiden mutation in severe infection and sepsis.

    abstract::In severe infection and sepsis, activation of coagulation frequently occurs, which contributes to the development of multiple organ dysfunction. Factor V Leiden is a relatively common mutation resulting in a mild prohemostatic state and consequently with an increased tendency to develop thrombosis. Hypothetically, pat...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0031-1297374

    authors: Levi M,Schouten M,van't Veer C,van der Poll T

    更新日期:2011-11-01 00:00:00

  • Diagnosis and Treatment of Trauma-Induced Coagulopathy by Viscoelastography.

    abstract::This article explores the application of viscoelastic tests (VETs) in trauma-induced coagulopathy and trauma resuscitation. We describe the advantages of VETs over conventional coagulation tests in the trauma setting and refer to previous disciplines in which VET use has reduced blood product utilization, guided prohe...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0040-1702171

    authors: Hartmann J,Walsh M,Grisoli A,Thomas AV,Shariff F,McCauley R,Vande Lune S,Zackariya N,Patel S,Farrell MS,Sixta S,March R,Evans E,Tracy R,Campello E,Scărlătescu E,Agostini V,Dias J,Greve S,Thomas S

    更新日期:2020-03-01 00:00:00

  • Case studies of HIT in cardiovascular medicine.

    abstract::We present three clinical cases that illustrate some of the key features of the diagnosis and management of immune-mediated heparin-induced thrombocytopenia (HIT). The importance of having a high clinical suspicion for HIT in the appropriate clinical setting is emphasized. Early therapeutic decisions should be based o...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2004-831040

    authors: Smith KJ,Call JT,Sane DC

    更新日期:2004-06-01 00:00:00

  • Thrombosis in myeloproliferative neoplasms.

    abstract::Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and i...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1370794

    authors: Falanga A,Marchetti M

    更新日期:2014-04-01 00:00:00

  • Recombinant peptides in thrombolysis.

    abstract::Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0030-1255447

    authors: Campbell J,Hilleman D

    更新日期:2010-07-01 00:00:00

  • Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.

    abstract::The extrinsic pathway is probably the predominant pathway in initiating blood coagulation in inflammatory lung diseases. Tissue factor pathway inhibitor (TFPI) is a Kunitz-type protease inhibitor of factor VIIa/tissue factor in the presence of factor Xa. As it has been shown recently that TFPI plasma levels are increa...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-996069

    authors: Cella G,Cipriani A,Tommasini A,Rampin E,Sbarai A,Rocconi R,Mazzaro G,Luzzatto G

    更新日期:1997-01-01 00:00:00

  • New-Onset Atrial Fibrillation and Adverse In-Hospital Outcome in Patients with Acute Pulmonary Embolism.

    abstract::Atrial fibrillation (AF) can be secondary to acute pulmonary embolism (PE). This study aimed to investigate the prognostic impact of new-onset AF on patients with acute PE. In this study, 4,288 consecutive patients who were diagnosed with acute PE were retrospectively screened. In total, 77 patients with acute PE and ...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-0040-1718397

    authors: Tang RB,Jing YY,Xu ZY,Dong JZ,Du X,Wu JH,Yu RH,Long DY,Ning M,Sang CH,Jiang CX,Bai R,Liu N,Wen SN,Li SN,Chen X,Huang ST,Cui YK,Ma CS

    更新日期:2020-11-01 00:00:00

  • Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.

    abstract:UNLABELLED:We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in Slovakia, where safe factor VIII (FVIII) concentrates have been used since 1990. A prospective study focused on inhibitor incidence in PUPs was established in 1997. Out of a total 61 PUPs born be...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,多中心研究

    doi:10.1055/s-0036-1581107

    authors: Batorova A,Jankovicova D,Morongova A,Bubanska E,Prigancova T,Horakova J,Machyniakova M,Cervenka J,Chandoga J,Böhmer D,Mistrik M

    更新日期:2016-07-01 00:00:00

  • Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links.

    abstract::The key reason behind the success of heparin in thrombosis and beyond is its polypharmacological sites of action for the prevention and treatment of multifactorial diseases that will only benefit slightly with single pharmacological mechanism-based agents. Thromboembolic disorders are driven by hypercoagulable, hypera...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-982084

    authors: Mousa SA

    更新日期:2007-07-01 00:00:00

  • Impact of automation on the quantitation of low molecular weight markers of hemostatic defects.

    abstract::Through in depth studies, the biochemical pathways of hemostasis-related systems have been elucidated in terms of well-defined molecular mechanisms. The interrelationships of coagulation, fibrinolytic, kallikrein-kinin, platelets, prostaglandins, blood vessel, and complement systems are now well understood. Methods ar...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:

    authors: Fareed J,Walenga JM,Bick RL,Bermes EJ Jr,Messmore HL Jr

    更新日期:1983-10-01 00:00:00

  • Plasminogen activator inhibitor-1 in aging.

    abstract::Plasminogen activator inhibitor-1 (PAI-1), a principal inhibitor of fibrinolysis, is induced in thrombotic, fibrotic, and cardiovascular diseases, which in turn primarily afflict the older population. This induction of PAI-1 may play an important role in the pathology of these diseases as PAI-1 can regulate the dissol...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-0034-1384635

    authors: Yamamoto K,Takeshita K,Saito H

    更新日期:2014-09-01 00:00:00

  • A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia.

    abstract::Essential thrombocythemia (ET) is a clonal myeloproliferative disorder of unknown origin primarily involving the megakaryocyte/platelet lineage. In an attempt to evaluate the role of the receptor c-mpl and its ligand thrombopoietin (TPO) in ET, various studies have been undertaken, the results of which are discussed h...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章,评审

    doi:10.1055/s-2007-996118

    authors: Griesshammer M,Bangerter M,Schrezenmeier H

    更新日期:1997-01-01 00:00:00

  • Thrombolytic activity of defibrotide against old venous thrombi.

    abstract::The age of the thrombus is probably a very important determinant of the outcome of thrombolysis. The clinical potential for rapidly dissolving thrombi by thrombolytic therapy is considerable because restoration of the blood flow can rescue the jeopardized district served by the occluded vessel such as for myocardial i...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 杂志文章

    doi:10.1055/s-2007-1002747

    authors: Niada R,Porta R,Pescador R,Mantovani M,Prino G

    更新日期:1989-10-01 00:00:00

  • Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma.

    abstract::The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecu...

    journal_title:Seminars in thrombosis and hemostasis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1055/s-2001-17952

    authors: Alban S

    更新日期:2001-10-01 00:00:00